Dr. Ou on Alectinib as Treatment for NSCLC

Video

In Partnership With:

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.

A phase II trial, evaluating alectinib was conducted in the United States in about 5 different medical centers. In the trial, named the AF-001JP study, 46 crizotinib-naive patients received treatment with alectinib starting at 300 mg twice daily and working up to 900 mg twice daily, Ou says. The recommended phase II dose is 600 mg twice daily.

The overall response rate (ORR) was 93.5% (95% CI, 82.1-98.6%) and the 12-month PFS rate was 83%. Of the 14 patients with CNS metastases at baseline, 64% remained progression-free after 12 months of treatment.

Ou says alectinib is also well tolerated. The only major grade 3 adverse event was neutrophil count decrease, which occurred in 7% of patients.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine